NCT00841048View on ClinicalTrials.gov

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

February 28, 2009

Study Completion Date

May 31, 2009

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

AZD4017

ascending multiple doses(start dose 75mg od), oral suspension

DRUG

Placebo

Trial Locations (1)

Unknown

Research Site, Gothenburg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00841048 - Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses | Biotech Hunter | Biotech Hunter